Lantern Pharma, Inc (NASDAQ: LTRN) Shares are Pushing Upward on News of FDA Authorization to Initiate Phase 2 of their Clinical Trial. The Stock is up over 18% at the Time of this Post.

July 14, 2022

[mstock id=”73007″ asset=”ltrn”]

Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer

https://www.businesswire.com/news/home/20220714005308/en/Lantern-Pharma-Receives-FDA-Authorization-to-Initiate-its-Phase-2-Clinical-Trial-Harmonic%E2%84%A2-for-LP-300-in-Never-Smokers-with-Non-Small-Cell-Lung-Cancer

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.